Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.

Journal of Alzheimer's disease : JAD - 1 Jan 2017

Sokolow Sophie, Li Xiaohui, Chen Lucia, Taylor Kent D, Rotter Jerome I, Rissman Robert A, Aisen Paul S, Apostolova Liana G

Abstract excerpt

BACKGROUND: Donepezil is an acetylcholinesterase inhibitor frequently prescribed for the treatment of mild cognitive impairment (MCI) though not approved by the Food and Drug Administration for this indication. In Alzheimer's disease, butyrylcholinesterase (BChE) activity increases with disease progression and may replace acetylcholinesterase function. The most frequent polymorphism of BChE is the K-variant,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoprotein E4
Share to Butyrylcholinesterase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cholinesterase Inhibitors

Share to Cognitive Dysfunction

Share to Indans

Share to Mental Status Schedule

Share to Outcome Assessment, Health Care

Share to Piperidines

Source

Open in PubMed Open full text

Identifiers

PMID: 27911294
DOI: 10.3233/JAD-160562
PMCID: PMC5534361

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.PMID 27911294Read ↗

Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.Semantic proximity Read ↗

Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.Semantic proximity Read ↗

Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.Semantic proximity Read ↗

Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer’s Disease—Could BCHE Genotyping Be Helpful in Alzheimer’s Therapy?Semantic proximity Read ↗

Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriersSemantic proximity Read ↗

Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.Semantic proximity Read ↗

Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients.Semantic proximity Read ↗

Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.Semantic proximity Read ↗

BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline.Semantic proximity Read ↗

Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.Semantic proximity Read ↗

Association between butyrylcholinesterase K variant and mild cognitive impairment in the Thai community-dwelling patients.Semantic proximity Read ↗

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.